Streetbeat News

Products Services

LQDA

UTHR

Traders are closely monitoring Liquidia (LQDA) as unconfirmed analyst comments suggest that United Therapeutics (UTHR) has filed a lawsuit against the FDA's action on Liquidia's lung-disease treatment Yutrepia, which is used for PAH and PH-ILD.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:24 pm

IWM

MNDY

SLAB

SYNA

The article discusses a potential shift from Big Tech to small-cap stocks, driven by expectations of a Federal Reserve rate cut in September. Andrew Graham of Jackson Square Capital highlights the iShares Russell 2000 ETF (IWM) and specific midcap stocks like Fabrinet (FN), Silicon Laboratories Inc (SLAB), Synaptics Inc (SYNA), and Monday.com Ltd (MNDY) as promising investments. The article also notes that the economic outlook and copper prices could influence the performance of these stocks.

Portfolio Pulse from Surbhi Jain

August 13, 2024 | 6:18 pm

TAP

TLRY

Tilray Brands, Inc. (NASDAQ:TLRY) has announced a definitive agreement to acquire four craft breweries from Molson Coors Beverage Company (NYSE:TAP). This strategic acquisition is expected to strengthen Tilray's craft beer leadership in the U.S. and solidify its position as the #1 craft brewer in the Pacific Northwest and Georgia. The acquisition is projected to grow Tilray's beverage division's new beer accounts by 30%. Financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:16 pm

ARTV

Artiva Biotherapeutics (NASDAQ:ARTV) recently priced its IPO at $12.00 per share, raising approximately $167 million. The company focuses on developing cell therapies for autoimmune diseases and cancers, with its lead program, AlloNK, currently in clinical trials. Needham and Wedbush have initiated coverage with bullish ratings and price targets of $23 and $18, respectively. Initial clinical results for AlloNK in lupus are expected in the first half of 2025.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 6:14 pm

BRAXF

BWVI

Zappy Zapolin, a prominent figure in the psychedelics space, discusses his transformative experiences with psychedelics and their therapeutic potential. He has advised companies like KetaMD, acquired by Braxia Scientific (OTC:BRAXF), and co-founded Psycheceutical Bioscience (OTC:BWVI). Zapolin advocates for the legal accessibility of psychedelic medicines to treat conditions like PTSD and addiction.

Portfolio Pulse from Nina Zdinjak

August 13, 2024 | 6:04 pm

PFE

Pfizer, Inc. (NYSE:PFE) shares are slightly up after the company reported positive top-line results for its ABRYSVO vaccine for RSV in immunocompromised adults. The Phase 3 MONeT trial showed strong neutralizing responses and a good safety profile.

Portfolio Pulse from Dylan Berman

August 13, 2024 | 6:00 pm

AZN

GSK

New EU regulations imposing stricter guidelines on medical trials, particularly limiting single-arm trials, could hinder the development of treatments for rare diseases. Nearly 40 organizations have urged revisions, emphasizing the importance of single-arm trials for rare disease research. Critics argue the guidelines could stifle innovation in rare disease treatment.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 5:58 pm

TAP

TLRY

Tilray Brands is reportedly in talks to acquire certain labels from Molson Coors, according to Bloomberg. This potential acquisition could expand Tilray's portfolio and market presence.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:51 pm

CNI

Canadian National Railway (CNI) has initiated a phased shutdown of its rail network in Canada, starting with an embargo on hazardous goods, due to stalled negotiations with unionized workers. The company may proceed with a lockout of employees if no progress is made by August 22.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:50 pm

BRKR

Asia's first 1.2 GHz NMR system has been installed at the Korea Basic Science Institute, significantly enhancing molecular and disease research capabilities.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:42 pm